Page 3 - Shilpa Biologicals News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Shilpa biologicals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Shilpa Biologicals Today - Breaking & Trending Today

Shilpa Medicare arm to make Sputnik V vaccine

Shilpa Medicare arm to make Sputnik V vaccine
thehindu.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thehindu.com Daily Mail and Mail on Sunday newspapers.

Stelis Biopharma , Shilpa Medicare , Shilpa Biologicals , Sputnik Lite , Virchow Biotech , Panacea Biotec , Gland Pharma , ஷில்பா மருத்துவ , ஷில்பா உயிரியல் , ஸ்பட்நிக் லைட் , சஞ்சீவி பயோடெக் , சுரப்பி பார்மா ,

India's Shilpa Medicare can make 100-200m doses of COVID-19 vaccine, says exec


 
 
Reuters
Published: 07 Apr 2021 02:43 PM BdST
Updated: 07 Apr 2021 02:43 PM BdST
AstraZeneca vaccine against coronavirus disease (COVID-19) is seen in Laakso hospital in Helsinki, Finland Mar 11, 2021. REUTERS
Indian drugmaker Shilpa Medicare Ltd has the capacity to manufacture 100-200 million doses of a protein-based vaccine for COVID-19, a company executive told Reuters on Wednesday.
);
}
India, the world s largest vaccine producing nation, has been ramping up the production of COVID-19 vaccines and global firms including AstraZeneca, US-based Novavax and Russia s RDIF have signed manufacturing deals with local players.
RDIF, in particular, has already announced deals with six Indian companies to make more than half a billion doses of its Sputnik-V vaccine, including major drugmaker Dr Reddy s Laboratories and several smaller firms. ....

Vinay Konaje , India National Stock Exchange , National Stock Exchange , Shilpa Biologicals , Shilpa Medicare , Fortune India , வினய் கொனஜே , இந்தியா தேசிய ஸ்டாக் பரிமாற்றம் , தேசிய ஸ்டாக் பரிமாற்றம் , ஷில்பா உயிரியல் , ஷில்பா மருத்துவ , அதிர்ஷ்டம் இந்தியா ,

Exclusive-India's Shilpa Medicare can make 100-200 million doses of COVID-19 vaccine, says exec


3 Min Read
BENGALURU (Reuters) -Indian drugmaker Shilpa Medicare Ltd has the capacity to manufacture 100-200 million doses of a protein-based vaccine for COVID-19, a company executive told Reuters on Wednesday.
Slideshow ( 2 images )
India, the world’s largest vaccine producing nation, has been ramping up the production of COVID-19 vaccines and global firms including AstraZeneca, U.S.-based Novavax and Russia’s RDIF have signed manufacturing deals with local players.
RDIF, in particular, has already announced deals with six Indian companies to make more than half a billion doses of its Sputnik-V vaccine, including major drugmaker Dr Reddy’s Laboratories and several smaller firms. ....

Shounak Dasgupta , Vinay Konaje , Sachin Ravikumar , Saumyadeb Chakrabarty , Thomson Reuters Trust Principles , Shilpa Medicare Ltd , India National Stock Exchange , National Stock Exchange , Shilpa Biologicals , Shilpa Medicare , Fortune India , Thomson Reuters Trust , ஷ்ௌுனாக் தாஸ்குப்தா , வினய் கொனஜே , சச்சின் ரவிகுமார் , தாம்சன் ராய்ட்டர்ஸ் நம்பிக்கை ப்ரிந்ஸிபல்ஸ் , ஷில்பா மருத்துவ லிமிடெட் , இந்தியா தேசிய ஸ்டாக் பரிமாற்றம் , தேசிய ஸ்டாக் பரிமாற்றம் , ஷில்பா உயிரியல் , ஷில்பா மருத்துவ , அதிர்ஷ்டம் இந்தியா , தாம்சன் ராய்ட்டர்ஸ் நம்பிக்கை ,